When we examined the survival of glioma patients according to the local expression of PRL or PRLR we found no significant changes, neither in the overall survival of PRL+ vs. PRL− GII-III or GBM patients (Fig. 7A,C), nor in the overall survival of PRLRHIGH vs. PRLRLOW (Fig. 7B,D). Here, PRLR is linked to central nervous system cancer.